Previous 10 | Next 10 |
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30...
2024-02-12 16:46:59 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Q4 2023 Earnings Preview Biogen scraps Aduhelm,...
2023-11-14 02:28:23 ET More on Design Therapeutics Design Therapeutics (DSGN) Investor Presentation - Slideshow Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therap...
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presen...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Design Therapeutics Inc. (DSGN) is expected to report $-0.42 for Q3 2023
2023-08-31 08:26:12 ET Prime Number Acquisition ( NCNC ) +39% . Allarity Therapeutics ( ALLR ) +35% . iCoreConnect ( ICCT ) +34% . NLS Pharmaceutics ( NLSP ) +19% . Tingo Group ( TIO ) +14% Reports Second Quarter 2023 Financi...
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Design Therapeutics, Inc. ("Design" or "the Company") (NASDAQ:DSGN). Investors who purchased Design securities are encouraged to obtain additional inf...
2023-08-15 15:02:00 ET Shares of Design Therapeutics (NASDAQ: DSGN) were down more than 69% as of 2:15 p.m. ET on Tuesday. The healthcare company announced phase 1 results for its Friedreich ataxia (FA) therapy, DT-216. The stock is down more than 78% so far this year. The c...
News, Short Squeeze, Breakout and More Instantly...
Design Therapeutics Inc. Company Name:
DSGN Stock Symbol:
NASDAQ Market:
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern arou...